Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A B Mehta

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
The British Journal of Dermatology|June 19, 2007
Fabry disease and the skin: data from FOS, the Fabry outcome surveyC H Orteu, T Jansen, O Lidove, et al.
British Journal of Haematology|February 1, 1991
Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantationH E Heslop, A S Duncombe, J E Reittie, et al.
Oncogene|May 6, 1998
Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cellsF A Riordan, C A Bravery, K Mengubas, et al.
British Journal of Haematology|September 13, 2001
Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cellsR G Wickremasinghe, K Ganeshaguru, D T Jones, et al.
Bone Marrow Transplantation|July 1, 1991
Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remissionM J Gilmore, M D Hamon, H G Prentice, et al.
Lancet (London, England)|July 9, 1988
Alpha-interferon therapy for essential thrombocythaemiaF J Giles, C R Singer, A G Gray, et al.
British Journal of Haematology|September 1, 1993
Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemiaE N McSweeney, F J Giles, C P Worman, et al.
British Journal of Cancer|October 1, 1989
A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual diseaseD J Gottlieb, M K Brenner, H E Heslop, et al.
Leukemia|October 27, 1997
Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment responseL Foroni, L A Coyle, M Papaioannou, et al.
Haematologica|June 22, 2001
The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patientsP Gameiro, S Vieira, P Carrara, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
The British Journal of Dermatology|June 19, 2007
Fabry disease and the skin: data from FOS, the Fabry outcome surveyC H Orteu, T Jansen, O Lidove, et al.
British Journal of Haematology|February 1, 1991
Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantationH E Heslop, A S Duncombe, J E Reittie, et al.
Oncogene|May 6, 1998
Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cellsF A Riordan, C A Bravery, K Mengubas, et al.
British Journal of Haematology|September 13, 2001
Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cellsR G Wickremasinghe, K Ganeshaguru, D T Jones, et al.
Bone Marrow Transplantation|July 1, 1991
Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remissionM J Gilmore, M D Hamon, H G Prentice, et al.
Lancet (London, England)|July 9, 1988
Alpha-interferon therapy for essential thrombocythaemiaF J Giles, C R Singer, A G Gray, et al.
British Journal of Haematology|September 1, 1993
Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemiaE N McSweeney, F J Giles, C P Worman, et al.
British Journal of Cancer|October 1, 1989
A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual diseaseD J Gottlieb, M K Brenner, H E Heslop, et al.
Leukemia|October 27, 1997
Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment responseL Foroni, L A Coyle, M Papaioannou, et al.
Haematologica|June 22, 2001
The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patientsP Gameiro, S Vieira, P Carrara, et al.
Pageof 14